DiscoverallergytalkPediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies miniseries Episode 3 – Long-Term Management and Prophylaxis for HAE
Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies miniseries Episode 3 – Long-Term Management and Prophylaxis for HAE

Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies miniseries Episode 3 – Long-Term Management and Prophylaxis for HAE

Update: 2024-12-13
Share

Description

Host: Kristin C. Sokol, MD, MS, MPH, FACAAI


Experts: Aleena Banerji, MD; Jonathan A. Bernstein, MD, FACAAI


 


Explore the strategies for long-term prophylaxis in pediatric HAE, including when to initiate treatment and the risks and benefits of various approaches. Transitioning care from childhood into adolescence and beyond is also discussed.


 


Learning Objective:


After listening to this podcast episode, participants should be better able to:



  • Employ strategies for long-term prophylaxis.


References:



  1. Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767.

  2. Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533.

  3. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3

  4. Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022


 


Speaker Disclosures:


Kristin C. Sokol, MD, MS, MPH, FACAAI


Advisor: Sanofi, Genentech, SELF/Conde Nast


 


Aleena Banerji, MD


Advisor: Astria, Biocryst, CSL Behring, Ionis, Intellia, Kalvista, Pharvaris, Takeda


Researcher: Astria, Ionis, Intellia


 


Jonathan A. Bernstein, MD, FACAAI


Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda


Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda


Researcher: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda, Teva


 


This podcast miniseries is supported by a grant from Takeda.

Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies miniseries Episode 3 – Long-Term Management and Prophylaxis for HAE

Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies miniseries Episode 3 – Long-Term Management and Prophylaxis for HAE

allergytalk